Navigation Links
A new anti diabetic drug on the anvil

India leads the top 10 countries estimated to have the highest number of diabetics in 2000 and 2030, with China and the US following closely. Type II Diabetes, one of the most common chronic diseases globally, is fast gaining // epidemic proportions throughout the world, with pathological manifestations including obesity, hypertension, hyperlipidemia and cardiovascular diseases. Since diabetes causes significant morbidity and mortality due to long-term micro and macro vascular complications, new drugs are required to combat it.

Glenmark Pharmaceuticals has recently filed for Phase I clinical trials for GRC 8200, its leading DPP-IV inhibitor compound, with the Medicines and Healthcare Products Regulatory Agency [MHRA] in the U.K. The dipeptidylpeptidase IV [DPP-IV] target is associated with glucose dependent insulin secretion and peripheral insulin resistance. While no DPP-IV inhibitor has been approved for marketing till date, among the scientific community DPP-IV inhibitors are expected to offer significant potential for being the therapy of choice, once approved.

The Phase I study will be conducted by Parexel U.K., a leading global CRO. The Phase I study is expected to be completed in February 2006 and will be conducted using single and multiple oral doses on healthy volunteers. The objective of this study is to assess the safety and bioavailability of GRC 8200 in humans. Pre-clinical studies have demonstrated GRC 8200 to be many times more potent than competing DPP-IV inhibitors. The compound is highly bioavailable and safe, displaying significant reduction in glucose excursion on oral glucose challenge. Pre-clinical studies have also demonstrated that GRC 8200 has the potential of being a long-acting compound with high selectivity to the DPP-IV target over DPP-II, VIII and IX.

Glenn Saldanha, Managing Director and CEO of Glenmark, states “We have a very aggressive timeline and hope to be the fourth to market with GRC 8200 in the DPP-IV class. We expect GRC 8200 to be launched on the US market in 2010.”
'"/>




Related medicine news :

1. Gastrointestinal ills more common in diabetics
2. Pollution- hazardous for diabetics
3. New treatment for diabetics
4. Breast screening among diabetic women
5. Needle free future for diabetics
6. Care for footwear not required diabetic patients
7. Nightlights could ward diabetic blindness
8. Gene variant foretells diabetic neuropathy
9. Protein in diabetic neuropathy treatment
10. New target for antidiabetic agents identified
11. Study links diabetics to increased risk of urinary tract infections
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/27/2017)... ... 2017 , ... Hotze Health & Wellness Center (HHWC), a ... New Guest Director. , Brandl is a dynamic and influential executive leader ... his professional career at Omnium Worldwide, now known as West Corporation, and handled ...
(Date:2/27/2017)... ... , ... The threat of nuclear warfare has long plagued this world. In ... underground testing of nuclear weapons. Years later, when her co-workers began dying, Dot started ... Nuclear Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear ...
(Date:2/27/2017)... China (PRWEB) , ... February 26, 2017 , ... Miro ... This pioneer sound and video system brings songs, movies, TV shows and much more ... sound offers clear, high-definition sound. An immersive view of 1280 x 720 provides crisp ...
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... for hair transplantation therapy, is proud to announce a new informational post on ... therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... for entries to the 7th Edition of International Social Design Awards. , ... Professionals, Product Designers, System Designers, Governments and Institutions worldwide with realized projects and ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... Co., Ltd., received a positive response from the ... design for RGN-137 to treat epidermolysis bullosa ("EB"). ... incorporates Thymosin beta 4 ("Tß4") as the active ...
(Date:2/27/2017)... , February 27, 2017 A recent research ... medical marijuana market alone is expected to reach a value of ... along with 28 states have legalized marijuana for medical ... Florida , North Dakota , ... were approved to use the drug in medical applications such as ...
(Date:2/27/2017)... PETACH TIKVAH, Israel , Feb. 27, ... a leading developer of adult stem cell technologies for ... S. Almenoff , M.D., Ph.D., FACP, and Arturo ... Directors.  "Dr. Almenoff and Mr. Araya ... at an exciting time for our company," said ...
Breaking Medicine Technology: